

Mid Atlantic Bio Angels (MABA)

SIDECAR FUND II

Life Science Parallel Fund

A Special Access Fund that co-invests alongside industry experts in early-stage private emerging life science companies



An Opportunity to Co-Invest with Industry Experts

MABA – Mid Atlantic Bio Angels (bioangels.net) – is an exclusive, invitation-only NY-based life science angel investment group that was formed in 2012 to bridge the expertise gap required by investors to make informed investment decisions in scientific, regulatory and commercially-complex healthcare investment opportunities. MABA invests exclusively in early stage, private life science companies (primarily therapeutics, devices, diagnostics and some digital health), with no geographic restrictions.

MABA's investment focus attracts a combination of members and experts who have deep domain knowledge in life sciences and makes the MABA membership one of the most experienced angel groups in the world. MABA's members perform due diligence and invest their own money both directly in portfolio companies and indirectly through the MABA's managed pools of capital ("Pools").

The Sidecar Fund allows investors and institutions who are not MABA members to passively invest alongside MABA members in the investments selected by (and invested in by) MABA members.

Access to A Unique Asset Class

The Mid Atlantic Bio Angels Sidecar Fund is an opportunity for investors and institutions to gain exposure to private Healthcare startup investments. Healthcare startups can be a significant source of investment returns, but the complexity associated with these investments requires both significant broad and specific industry expertise. Our investment group uses the collective knowledge of our group members to jointly research every investment opportunity. Our collective research approach enables a differentiated process and construct than most traditional venture investing entities or angel groups with broad investment interests. The depth of understanding that those engaged daily in the health care industry bring to the investment decision provides a unique insight and advantage to investors.

Fund Highlights

- Provides access to MABA's proprietary deal flow
- Provides diversification - minimum of five investments in a Fund investor's portfolio
- Timeline & Risk Profile diversification – likely to include a mix of early and later stage companies
- Provides access to unique asset class: early stage, private life science companies
- Parallels MABA members' investments, most of whom are industry members
- Invests side by side in companies that were diligenced by and received investment from MABA
- Co-invests on the same terms as MABA member investors
- Allows additional, company-specific investments at an investor's discretion
- Low administrative fees and very low internal operational expenses

Terms

Fund	MABA Sidecar Fund II
Fund Size	Fluctuating, open-ended fund, accepting contributions on a rolling basis
Investment Objectives	Access fund parallels MABA members' and Pools' investments in early-stage, private, life science companies (primarily therapeutics, devices, diagnostics and digital health), with no geographic restrictions
Investment Mechanism	Sidecar Fund II parallels MABA when MABA members make an investment that meets co-investment thresholds.
Fund Contributions	\$50,000 minimum
Eligibility	Must be an Accredited Investor or Qualified Purchaser (as defined by the SEC)
Closing	None. Accepting contributions on a rolling basis
Investing Period	Investor funds expected to be invested within approximately two years of receipt
Funding	Fully funded up front. No subsequent capital calls. Additional, company-specific investments allowed, at Fund investor's discretion
Term	Open-ended
Administrative Fee	Average Administrative Fees: 0.50% (2.00% in years 1-2, 1.00% in year 3, 0% in years 4-10) Low internal Operational Expenses.
Performance Fee (Carry)	20% carried interest, after 100% return of portfolio company investment-related capital contributions
Distributions	Pro rata, upon portfolio company exit and/or distributions from portfolio company

Investments in early stage private life science companies carry with them a significant amount of risk, including risk of total investment loss.

Prospective Sidecar Fund investors may be asked to provide information to substantiate their Accredited Investor or Qualified Purchaser status, as defined by the SEC, at the time the contribution is made, and to keep the Sidecar Fund informed should this status ever change during the life of the Sidecar Fund.

MABA's investment techniques, analyses, and judgments may not produce the outcomes we intend. The investments we select for the fund may not perform as well as other securities that we do not select for the fund. We, or the fund's other service providers, may experience disruptions or operating errors that could have a negative effect on the fund. You can lose money by investing in the fund. For informational purposes only. Not an investment recommendation.

For further information, please contact: Yaniv Sneor
sidecarfunds@bioangels.net
908-913-0193